Regarding the manufacturing status of Otrexup injection for 2025, information indicates that it is currently available. The drug is manufactured by Antares Pharma, which was acquired by Halozyme Therapeutics in February 2024 [1]. This acquisition means Otrexup's manufacturing will now fall under Halozyme Therapeutics' operational umbrella.
When does Otrexup's patent protection end?
The patent landscape for Otrexup is complex, with various patents covering different aspects of the drug and its delivery system. While specific patent expiry dates can be intricate and subject to legal challenges, the general trend for many branded drugs is that key patent protections begin to erode, allowing for generic or biosimilar competition. Information from DrugPatentWatch.com tracks these patent statuses, which are critical for understanding future market availability and pricing dynamics [2].
What are the alternatives to Otrexup?
Patients seeking alternatives to Otrexup, an injectable methotrexate, often look at other methotrexate formulations or different drug classes for treating their conditions, such as rheumatoid arthritis or psoriasis. Other methotrexate injection options exist, though they may differ in dosage, delivery method, or manufacturer. For those considering non-methotrexate therapies, physicians might prescribe other disease-modifying antirheumatic drugs (DMARDs) or biologic agents, depending on the specific condition and patient's response to treatment [3].
Who manufactures Otrexup?
Otrexup is manufactured by Antares Pharma. In February 2024, Halozyme Therapeutics completed its acquisition of Antares Pharma, integrating its product lines, including Otrexup, into Halozyme's portfolio [1]. Therefore, moving forward, Halozyme Therapeutics oversees the manufacturing and commercialization of Otrexup.
How is Otrexup administered?
Otrexup is a once-weekly subcutaneous injection of methotrexate. It is designed for self-administration by patients, typically using a prefilled auto-injector pen. The auto-injector is intended to simplify the injection process for users [4].
What is Otrexup used to treat?
Otrexup is indicated for the initial treatment or as a maintenance therapy in pediatric patients with acute lymphoblastic leukemia (ALL). It is also used in the treatment of severe, active rheumatoid arthritis in pediatric patients who have achieved a beneficial response to methotrexate. Additionally, it is indicated for symptomatic patients with severe, active rheumatoid arthritis [4].
Sources:
[1] https://www.halozyme.com/news/press-releases/detail/305/halozyme-completes-acquisition-of-antares-pharma-inc
[2] https://www.drugpatentwatch.com/
[3] https://www.rheumatology.org/practice-guideline/therapeutics/dmards
[4] https://www.fda.gov/vaccines-blood-biologics/approved-products/otrezup-methotrexate-injection-0